Johnson & Johnson (NYSE:JNJ) Releases Quarterly Earnings Results, Meets Expectations

Posted by Amy Steele on Jan 21st, 2026

Johnson & Johnson (NYSE:JNJ – Get Free Report) released its quarterly earnings data on Wednesday. The company reported $2.46 earnings per share for the quarter, meeting the consensus estimate of $2.46, FiscalAI reports. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.56 billion for the quarter, compared to analyst estimates of $24.14 billion. During the same quarter in the prior year, the business earned $2.04 EPS. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. Johnson & Johnson updated its FY 2026 guidance to 11.430-11.630 EPS.

Here are the key takeaways from Johnson & Johnson’s conference call:

Johnson & Johnson reported a very strong 2025 (FY sales of $94.2B, Q4 sales $24.6B) and issued 2026 guidance calling for ~5.7%–6.7% operational sales growth with a midpoint near $100B and adjusted EPS guidance centered around $11.28–$11.48 (reported ~ $11.53 at midpoint).
Innovative Medicine is driving momentum — oncology grew rapidly (21% in 2025) with Darzalex topping ~$14B, Carvykti has treated >10,000 patients, Tecvayli showed very strong phase‑3 results, and immunology leader Tremfya accelerated (Q4 +65%) and passed $5B in 2025 with a path to >$10B.
MedTech transformation is advancing with ~$34B in 2025 sales, strong performances from Abiomed and Shockwave, commercial traction for VARIPULSE, and strategic regulatory progress including the Ottava De Novo submission and planned Monarch urology robotics launch that underpin future growth.
Material legal and cost headwinds remain — the talc MDL produced a mixed Daubert report that J&J will appeal, litigation costs rose (noted ~$0.9B), and near‑term P&L pressures include elevated tariffs (≈$500M guidance for 2026) plus a higher diluted share count (~2.44B shares) that creates EPS headwinds and ongoing uncertainty.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $218.12 on Thursday. The stock has a market cap of $525.52 billion, a price-to-earnings ratio of 21.05, a P/E/G ratio of 2.24 and a beta of 0.34. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $220.11. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The business’s 50-day simple moving average is $207.39 and its 200 day simple moving average is $188.27.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s payout ratio is currently 50.19%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Abel Hall LLC acquired a new position in Johnson & Johnson during the third quarter worth $419,000. Harvest Investment Services LLC increased its stake in shares of Johnson & Johnson by 21.4% during the 3rd quarter. Harvest Investment Services LLC now owns 2,826 shares of the company’s stock worth $524,000 after purchasing an additional 499 shares during the last quarter. Keystone Financial Group raised its holdings in shares of Johnson & Johnson by 10.1% in the 3rd quarter. Keystone Financial Group now owns 51,405 shares of the company’s stock valued at $9,774,000 after purchasing an additional 4,733 shares during the period. Conservest Capital Advisors Inc. acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $211,000. Finally, Morningstar Investment Management LLC grew its holdings in Johnson & Johnson by 1,999.4% during the third quarter. Morningstar Investment Management LLC now owns 98,377 shares of the company’s stock worth $18,241,000 after purchasing an additional 93,691 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on JNJ. The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Argus set a $210.00 target price on Johnson & Johnson in a research report on Wednesday, October 15th. Stifel Nicolaus upped their price target on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Raymond James Financial lifted their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Finally, Guggenheim upped their target price on Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $213.33.

Check Out Our Latest Report on Johnson & Johnson

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Q4 revenue beat and 2026 guidance above consensus — management raised FY2026 sales and EPS targets, signaling mid‑single‑digit organic growth and margin improvement. Johnson & Johnson reports Q4 and Full-Year 2025 results
Positive Sentiment: MedTech and oncology drove top‑line strength (MedTech up mid‑single digits; strong Darzalex and other cancer drug growth), supporting the company’s revenue trajectory beyond STELARA. Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth
Positive Sentiment: Technicals and analyst sentiment remain constructive — MarketBeat highlights a trend‑following buy signal and rising analyst price targets, which could limit downside and support future upside. Johnson & Johnson Quietly Triggers a Trend Following Buy Signal
Neutral Sentiment: EPS outcome was mixed: adjusted EPS roughly in line (small beat vs. some consensus figures) and margins broadly as expected — solid but not overpowering enough to eliminate near‑term concerns. Johnson & Johnson (JNJ) Tops Q4 Earnings and Revenue Estimates
Negative Sentiment: Talc litigation advanced this week as plaintiffs cleared a key expert testimony hurdle — a reminder of legacy legal risk that can create episodic share pressure and potential liabilities. Johnson & Johnson Talc Plaintiffs Clear Key Expert Testimony Hurdle
Negative Sentiment: STELARA sales plunged after loss of exclusivity and biosimilar competition (material YOY decline), which is a sizable headwind given STELARA’s previous revenue contribution. That dynamic is a key reason shares traded down despite the beat. J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales
Negative Sentiment: Company flagged a hit from a recent drug‑pricing deal with the administration (described as “hundreds of millions” of dollars), which tempers net profit upside and adds near‑term uncertainty. Johnson & Johnson forecasts 2026 profit above Wall Street estimates

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.